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Abstract 
Introduction: HER2 overexpression is present in 7 to 34% of gastric carcinomas. Several studies have 
demonstrated associations between HER2 overexpression and clinicopathological variables, including tumor 
depth, lymph node metastasis, and intestinal morphology. HER2 overexpression has been linked to shorter 
survival. 
Aim:  In this study, we aimed to determine the frequency of HER2 overexpression in patients with metastatic 
gastric carcinoma referred to our clinic, to assess HER2 expression using immunohistochemistry (IHC) or silver 
in situ hybridization (SISH) and to demonstrate potential associations between HER2 expression and 
histopathological parameters. 
Materials and Methods: In this study, we assessed archival samples from 120 patients diagnosed with metastatic 
gastric carcinoma between 2015 and 2019 and tested for HER2 status. Samples had been obtained by endoscopic 
biopsy in 84 patients and gastric resection in 36 patients, whereas 36 patients were diagnosed in other health 
facilities and were referred to our department for consulting. Hematoxylin-eosin stained preparations were 
reassessed, and diagnoses were confirmed based on World Health Organization (WHO), and Lauren classifications 
and HER2 results were compared to previous results. 
HER2 status was assessed by immunohistochemistry (IHC) or silver in situ hybridization (SISH) in available 
paraffin-embedded tumor sections. Associations between HER2 expression levels and age, sex, tumor location,  
size and histological type of the tumor, lymphovascular,  perineural and perinodal invasion and perinodal invasion, 
lymph node metastasis, and site of metastasis. 
Results: 84 (70%) out of 120 patients with metastatic gastric carcinoma were male, and 36  (30%) were female, 
and the mean age was  60.7 years  (age range: 21-90 years).  84 patients had undergone an endoscopic biopsy, and 
36 patients had undergone gastric resection, whereas 39 patients were diagnosed in other health facilities and were 
referred to our department for consulting. 
In total 31(25.8%) out of 120 subjects tested positive for HER2 overexpression 
Comparisons of histological patterns, according to Lauren's classification, indicated that intestinal type was 
predominant in both groups, and none of the diffuse gastric carcinomas was HER2 positive. A statistically 
significant intergroup difference was found with respect to the prevalence of diffuse gastric carcinoma (p=0.03). 
Conclusion: In our study, HER-2 gene amplification (25.8%) is compatible with the literature. Her2 positive 
tumors were mostly located proximally and were not observed in diffuse type. In this respect, they were found 
statistically significant. 
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INTRODUCTION 
Gastric Carcinoma is the fourth most common malignant tumor worldwide after lung, breast, colorectal and 
prostate cancers and ranks fifth among the most common cancers in Turkey. Gastric Carcinoma is the third 
common cause of cancer deaths worldwide and the fourth common cause of cancer deaths in our country (1,2). 
Despite diagnostic and therapeutic advances in gastric carcinoma, the prognosis is poor, particularly in patients 
with advanced disease; targeted therapies have been developed to improve the response rate in these patients. 
HER2 gene is a potential target in gastric carcinoma, and HER2 gene amplification is under investigation in various 
tumors. 
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The proto-oncogene HER2 located on the long arm of the seventeenth chromosome encodes the erbB2 
receptor protein in the cell membrane. The erbB2 receptor protein is one of the epidermal growth factor receptors, 
and once activated, it affects cell differentiation, apoptosis, cell adhesion, migration, and growth functions through 
tyrosine kinase. The erbB2 receptor protein is within the signaling pathways that take part in cell proliferation and 
is a driver in various cancer types. An increase in the number of HER2 receptors overexpression of the receptor 
on the plasma membrane compared to normal cells, is investigated with immunohistochemistry techniques in 
pathology practice (3,4). An increased copy number of the gene encoding the receptor protein in the nucleus, 
namely gene amplification is investigated with in situ hybridization (ISH) techniques including fluorescence ISH 
(FISH), chromogenic ISH (CISH) and silver- enhanced ISH (SISH) (5). 
The determination of HER2 status has become a standard practice in breast cancers, as it can provide 
predictive and prognostic information. HER2 receptor blockade in cancer cells in HER2-positive breast tumors 
may help to inhibit these signaling pathways and prevent tumor cell proliferation. Trastuzumab, an anti-HER2 
receptor antibody, has been widely used in HER2 overexpressing breast cancers. HER2-overexpression and 
amplification analyses have been starte in advanced gastric cancers after the determination of their predictive value 
(6, 7) 
HER2 overexpression is present in 7 to 34% of gastric carcinomas. Several studies have demonstrated 
associations between HER2 overexpression and clinicopathological variables, including tumor depth, lymph node 
metastasis, and intestinal morphology. HER2 overexpression has been linked to shorter survival (6, 8, 9, 10, 11). 
In this study, we aimed to determine the frequency of HER2 overexpression in patients with metastatic gastric 
carcinoma referred to our clinic, to assess HER2 expression using immunohistochemistry (IHC) or silver in situ 
hybridization (SISH) and to demonstrate potential associations between HER2 expression and histopathological 
parameters. 
 
MATERIALS AND METHODS 
In this study, we assessed archival samples from 120 patients diagnosed with metastatic gastric carcinoma between 
2015 and 2019 and tested for HER2 status. Samples had been obtained by endoscopic biopsy in 84 patients and 
gastric resection in 36 patients, whereas 36 patients were diagnosed in other health facilities and were referred to 
our department for consulting. Hematoxylin-eosin stained preparations were reassessed, and diagnoses were 
confirmed based on World Health Organization (WHO), and Lauren classifications and HER2 results were 
compared to previous results. 
HER2 status was assessed by immunohistochemistry (IHC) or silver in situ hybridization (SISH) in available 
paraffin-embedded tumor sections. Associations between HER2 expression levels and age, sex, tumor location,  
size and histological type of the tumor, lymphovascular,  perineural and perinodal invasion and perinodal invasion, 
lymph node metastasis, and site of metastasis. 
 
Methods for Evaluating HER2 Status 
HER2 immunohistochemistry (IHC) has been performed in all cases, as requested by their primary oncology clinic.  
Anti-HER2/neu (4B5) rabbit monoclonal antibody (Ventana) was used for IHC staining.  
A scoring system proposed by Hoffmann et al. was used for the assessment of HER2 status in gastric 
carcinoma samples (3, 5). This is a 0 to 3 immunohistochemistry scoring system (Table1). SISH was performed 
in samples with a  IHC score of +2 or +3. In SISH assessments, HER2 signals and chromosome 17 signals were 
counted in at least 20 cells, and HER2/CEP17 ratio was calculated. Samples were considered HER2 positive if the 
HER2/CEP17 ratio calculated by SISH was ≥2. If the IHC score was 0 or +1, the tumor was considered HER2 
negative, and SISH was not performed in these samples. 
 
Statistical Analysis: 
A GraphPad Prism software package 5.00 was used for statistical analyses. A p-value less than 0.05 was considered 
statistically significant. The Shapiro-Wilk test was used to determine if the data were normally distributed. One-
way variance analysis was used to compare means of more than two groups, and two-way ANOVA analysis was 
used to compare two independent groups.      
 
RESULTS  
84 (70%) out of 120 patients with metastatic gastric carcinoma were male, and 36  (30%) were female, and the 
mean age was  60.7 years  (age range: 21-90 years).  84 patients had undergone an endoscopic biopsy, and 36 
patients had undergone gastric resection, whereas 39 patients were diagnosed in other health facilities and were 
referred to our department for consulting. 
The most common site of metastasis was the liver (33%), followed by the esophagus (9.4%). Other sites of 
metastases are shown in Table 2. 
Preparations were assessed in terms of HER2 overexpression  54 (45%) subjects  tested negative for HER2 
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expression (IHC 0, +1), 48 (40%)  patients  were suspicious for HER2 overexpression  (IHC +2) and 18 (15%)  
tested positive for HER2 expression (IHC +3). SISH was negative in samples from 37 (77) subjects who scored 
+2 in ICH and SISH was positive in samples from 11 (23%) subjects (Figure1). HER2 amplification was detected 
by SISH in all of 20 subjects (100%) who scored +3 in IHC (Figure2). 
In total 31(25.8%) out of 120 subjects tested positive for HER2 overexpression (Table 3). 
The tumor was located in the gastric antrum in 55 subjects (46%), in the cardia in 29 subjects (24.2), in the 
gastric fundus in 20 subjects (16.6%), and cancer involved the entire stomach in 16 subjects (13.3%)  (Table 4). 
Based on WHO classification, the histologic pattern of gastric carcinoma was tubular in 82 subjects (68.3%), 
signet-ring cell pattern in 18 (15%), mucinous in 6 subjects (5%), a mixed pattern in 13 subjects (10.8%) and 
papillary in 1 subjects (Table 4). 
Based on Lauren's classification, 89 subjects (74%) had intestinal-type carcinoma, 18 subjects (15%) had 
diffuse-type carcinoma, and 13 subjects (10.8%) had mixed type carcinoma (Tablo4). 
Among 36 subjects who had undergone gastric resection vascular invasion was detected in 23 subjects  
(63.8%), lymphatic invasion was detected in 27 subjects (75%)  and perineural invasion was detected in 23   
subjects  (63.8%). Regional lymph node involvement was observed in 33 subjects (%91) (Table 4) 
The assessment of clinical and clinicopathological characteristics of HER2 positive subjects revealed that 24 
subjects were male (77.4%) and 7 subjects were female (22.5%). The mean age of HER2-positive study subjects 
was 62.8 years. 
Among subjects with liver metastases, 11 (28.94%) had HER2 positive tumors, and among subjects with 
esophageal metastases 7 (63.6%) subjects HER2 positive tumors (Table 2). Among subjects with HER2 positive 
gastric carcinoma, the tumor was located in the cardia in 16 subjects (51.6%). 29 (93.5%) subjects had intestinal 
type carcinoma based on Lauren's classification, and none of the subjects  with diffuse-type carcinoma tested 
positive for HER2 overexpression. The mean tumor diameter was 5.8 cm (range: 2.5-9 cm). Angio-invasion was 
detected in seven subjects (22.5%), lymphatic invasion was detected in 8 subjects (25.8%), and perineural invasion 
was detected in 4subjects (17.4%) (Table 5). 
No statistically significant differences were found between  HER2 positive subjects and HER2 negative 
subjects in age, sex, tumor diameter, T stage, and lymph node metastases. The analysis of tumor location revealed 
that HER2 positive tumors were more likely to occur in the cardia, whereas HER2 negative tumors were more 
common in the gastric antrum, and a significant difference was found between the two groups in tumor locations 
(p=0.03). (Figure 3a) 
Comparisons of histological patterns, according to Lauren's classification, indicated that intestinal type was 
predominant in both groups, and none of the diffuse gastric carcinomas was HER2 positive. A statistically 
significant intergroup difference was found with respect to the prevalence of diffuse gastric carcinoma (p=0.03). 
(Figure 3b) 
Comparisons of histological types based on WHO classification revealed that 93 subjects (77.5%) had tubular 
gastric carcinoma, of which 21 (22.58%) tested positive for HER2 overexpression. No significant difference was 
found between the two groups. Tubular tumors were poorly differentiated in both groups  (Figure3c). 
No statistically significant differences were found between HER2 positive and HER2 negative groups in 
angioinvasion, lymphatic invasion, and perineural invasion.  
All tumors were considered to be stage 4 (T4) as distant metastases were found in all subjects. Lymph node 
involvement was detected in 27 subjects (75%). Lymph node involvement was less common in HER2-positive 




In many patients, gastric carcinoma is diagnosed at advanced and metastatic stage. According to the International 
Agency for Research on Cancer (IARC), 951,000 new diagnoses of gastric carcinoma were made worldwide in 
2012, and 723.000 of these cases resulted in death. Gastric carcinoma ranks fifth among the most common cancers 
and ranks third among the most common causes of cancer death worldwide. More than 70% of all cases of gastric 
carcinoma are diagnosed in developed countries (12). 
Overexpression of HER2 oncoprotein in gastric carcinoma was first defined in 1986. Various studies have 
demonstrated that oncoproteins might play a role in the development of gastric carcinoma (9). 
The addition of anti-HER2 (Human epidermal growth factor-2) monoclonal antibody Trastuzumab to 
chemotherapy has been demonstrated to improve survival in studies aiming to develop new treatment modalities 
as an adjuvant to chemotherapeutic agents.  
HER2 gene amplification has been reported to occur in gastric carcinoma at rates varying between 7% and 
34%.  This variability may occur as a result of various factors, including sample size, tumor heterogeneity, 
differences in patient populations, and differences in methods or scoring systems used in the study (6). 
HER2 expression rate was found to be 22.1% in the ToGA study investigating the basis for the use of anti-
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HER2 therapy in gastric carcinoma in 3807 patients with gastric carcinoma from 24 countries, HER2 expression 
rate was found to be 22.1% (6). HER2 expression rate was found to be 29.5% by Ljuubomir Ognjenovic et al.(12) 
and 8% by Tevfik et al. (13). In line with the literature, the prevalence of HER2 gene amplification in gastric 
carcinoma was found to be 25.8% in this study. 
Gastric carcinoma is more likely to occur over the age of 60 years and in males, and no significant differences 
have been observed between patients with HER2 positive gastric carcinoma and patients with HER2 negative 
gastric carcinoma regarding age and gender predilection (7,13,14). In this study, 70% of study subjects were males 
with a mean age of 62.8 years. 
Many recent publications are reporting that gastric carcinomas are more likely to occur in the proximal 
stomach (9,15,16) Isabel A et al. reported that tumors were more common in the proximal stomach in a publication 
on HER2 expression investigated in 93 patients with gastric carcinoma (9). The prevalence of HER2 expression 
was found to be 34% in tumors located in the proximal stomach and 20% in tumors located in the distal stomach 
in the ToGA study, which included patients with gastric carcinoma from 122 sites in 24 countries (6). In our study, 
44.4% of HER2 positive tumors were located in the proximal stomach, whereas 84.4% of HER2-negative tumors 
were located in the distal stomach in line with the literature, and a statistically significant intergroup difference 
was detected in tumor locations  (p=0.016). (Table 4) 
Several studies have reported an association between HER2 overexpression and poor prognosis (8,9,10,11), 
whereas no statistically significant association was found between HER2 overexpression and poor prognosis in 
many studies  (13,14,15,16,17,18,19). 
In a meta-analysis of 41 studies including 17.494 subjects Yu-Ying Lei et al.   determined that there was no 
statistically significant association between a positive HER2 overexpression and age, tumor size, lymphovascular 
and neural invasion. In contrast, statistically significant associations were found between  HER2 overexpression 
and sex, tumor locations, TNM stage system, distant metastasis, lymph node metastasis, Lauren's classification, 
and the degree of tumor differentiation. In that study investigators concluded that tumors tested positive for HER2 
were associated with poor prognosis (11). In our study gastric carcinomas were of intestinal type by Lauren’s 
classification and none of the cases of diffuse gastric carcinoma tested positive for HER2. Therefore, a statistically 
significant intergroup difference was found in histological types by Lauren’s classification (p=0.03) (Table 4). 
Meltem B et al. assessed potential associations between HER2 status  by immunohistochemistry and FISH 
(Fluorescence in situ hybridization) and clinical and pathological parameters and prognosis in 598 subjects with 
gastroesophageal carcinoma. The rate of HER2 positive tumors was found to be 15%, and unlike other studies in 
the literature, no significant differences were found between proximal and distal locations of the tumor. HER2  
overexpression was more likely to be significant in well-differentiated tumors and tumors of intestinal-type 
compared to poorly differentiated tumors, and no significant associations were found between HER 2 
overexpression and other prognostic factors (17). In our study, all subjects had poorly differentiated tumors and 
no statistically significant differences were found between HER2 positive and HER2 negative subjects in terms of 
lymphatic, perineural, and vascular invasion (Table 5).  
Tevfik K. et al.  investigated the prevalence of HER2 overexpression and clinical parameters and prognosis. 
They determined that 52% of tumors were located in the distal stomach and HER2 overexpression had no 
significant effects on overall and disease-free survival. (13) 
 In several studies, HER2 overexpression was observed in well-differentiated and moderately differentiated 
gastric carcinoma tumors (7,13,14,15,16,19), whereas poorly differentiated tumors were found to overexpress 
HER2 in other studies (8,10,11,18).  Tumors overexpressing  HER2  in our study were poorly differentiated and 
no significant difference was found between HER2 positive and HER2 negative subjects in tumor differentiation. 
Chao He et al. reported higher rates of HER2 positivity (26.47%) in poorly differentiated gastric carcinoma 
without lymph node metastasis, although many studies have reported numerically higher rates of lymph node 
metastasis in subjects with HER2 positive tumors (7). In our study, the prevalence of lymph node metastasis was 
higher in subjects with HER2- negative tumors (77.7%) compared to those with HER2-positive tumors. 
W.Q Sheng et al. investigated clinicopathological characteristics and HER2 status in 726 subjets with gastric 
cancer from 4 different clinics representative of four different geographic regions of China. The prevalence of 
HER2 positivity correlated with sex, tumor location, histological grade, and Lauren’s classification and HER 
positivity was more common in gastric carcinoma of intestinal type, well and moderately differentiated tumors, 
gastroesophageal carcinomas and in males. No statistically significant associations were found between HER2-
positive status and advanced age, lymph node metastasis, pT stage, pN stage or pM stages (16). 
Although conflicting results have been reported in the literature, it is remarkable that HER2 positive tumors 
are of Lauren’s intestinal morphology, are moderately differentiated or well-differentiated, are located in the 
proximal stomach, and associated with lymph node metastasis and advanced pT stage (15,16). In our study, tumors 
overexpressing HER2 were poorly differentiated, mostly were of intestinal morphology and located in the cardia.  
HER2 overexpression was not detected in any cases of diffuse stomach carcinoma. However, no statistically 
significant associations were found between HER2 overexpression and histopathological parameters. These 
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differences among studies might be associated with geographic characteristics, sample size, study methods, and 
also suggest that HER2 might be a prognostic factor in stomach carcinoma. 
This study was performed to determine the prevalence of HER2 overexpression, which might show 
geographic variations, to perform a comparative analysis of HER2 expression by immunohistochemistry (ICH) 
and silver in situ hybridization and to reveal potential associations between HER2 overexpression and 
clinicopathological parameters. 
HER2 positive status has been comprehensively investigated in breast cancer and it has long been considered 
to be a poor prognostic factor. Trastuzumab is known to improve survival in patients with primary or metastatic 
HER2 positive breast cancer (6, 10, 13). Besides, many studies demonstrated that the addition of Trastuzumab to 
chemotherapy might improve survival in advanced stomach cancers and gastroesophageal junction cancers, and 
further studies on various pathways may be guiding. 
Table1: IHC scoring criteria for HER2   
Score Staining Pattern HER2 status 
0 No staining Negative 
1+ In > 10% of cells, membranous, faint  Negative 
2+ In > 10% of cells, membranous, moderate, basolateral/lateral Indefinite 
3+ In > 10% of cells, membranous intense, basolateral/lateral Positive 
 
Table 2: Sites of metastasis and their frequency in gastric carcinoma 
Site of Metastasis Number 
(%) 
HER2 (+)(%) HER2 
(-)(%) 
Liver 38 (32.47) 11 (28.4) 25 (65.78) 
Esophagus  11 (9.4) 7 (63.6) 4 (36.36) 
Omentum 10 (8.54) 3 (30) 7 (70) 
Bone 9 (7.69) 3 (33.33) 6 (66.67) 
Lung 9 (7.69) 2 (22.22) 7 (77.78) 
Colon 6 (5.12) - 6 (100) 
Ovary 4 (3.41) - 4 (100) 
Pleura 4 (3.41) 2 (50) 2 (50) 
Breast 1 (0.85) 1 (100)  
Peritoneum 4 (3.41)   
Pancreas 2 (1.71) 2 (100)  
Soft Tissue 2 (1.71) - 2 (100) 
 
Table 3: HER2 Analysis in gastric tumor tissues: 
 IHC 0/1+       IHC 2+     IHC 3+ Total N (%)  
SISH positive    0   11(23%) 20(100%)   31(25.8)         
SISH negative   52(100%)    37(77%)    0   89 (75%) 
Total  52(43.3%)   48(40%) 20(16.6%)     120 
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Age (mean) 60.7 62.8 60.1  
Sex      
           Male 84 (70)    
           Female  36 (30)    
Tumor location    0,030 
          Antrum 58 (48.33) 9 (15.51) 49 (84.48)  
          Body 19 (15.83) 5 (26.31) 14 (73.68)  
          Cardia  36 (30) 16 (44.44) 20 (55.56)  
         Entire   stomach  7 (5.83) 1 (14.28) 6 (85.71)  
Lauren’s classification    0,03 
          Intestinal  97 (80.83) 29 (29.89) 68 (70.10)  
 Diffuse-mixed 19-4 (19.16) 2 (8.69) 21 (91.30)  
WHO classification    0,32 
Tubular  93 (77.5) 21 (22.58) 72 (77.41)  
           Well-differentiated 3 (3.22) 1 (33.33) 2 (66.67)  
     Moderately-differentiated                       38 (40.86) 13 (34.21) 17 (44.73)  
           Poorly-differentiated 52 (55.91) 17 (32.69) 45 (86.53)  
Papillary  1 (0.83) 1 -  
Mucinous 4 (3.33) 1 (25) 3 (75)  
Signet ring cell-Poor cohesive carcinoma   19 (15.83) 1 (5.26)    18 (94.73)  
Mixed 3 (2.5) 1 (33.33) 2 (66.67)  
Tumor size 7.5cm (17.5-2.5) 5.8cm (9-2.5) 8.4cm (15.5-2.5) 0.11 
 
Table 5: Comparisons clinical and pathological parameters  between HER2 positive and HER2-negative subjects 
who undergone gastric resection  





Vascular invasion            0.71 
 Positive 23(63.88) 7(30.4) 16 (69.6)  
Negative  13(36.11) 3(23) 10 (77)  
Perineural invasion    0.11 
 Positive 23(63.88) 4(17.4) 19(82.6)  
Negative  13(36.11) 6(46.1) 7(53.9)  
Lymphatic invasion    1 
 Positive 27(75) 8(29.6) 19(70.3)  
Negative  9(25) 2(22.3) 7(77.7)  
    0.32 
Lymph node metastasis  27(75%) 6(22.3%) 21(77.7%) 
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FIGURE3c:HER2 state by degree of differentiation 
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